Immutep remains a high-risk, pre-revenue biotechnology firm heavily reliant on milestone-driven funding to sustain its intensive LAG-3 oncology research pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 30, 2026 | -$0.17-550.0% vs -$0.03 | $10M-15.0% vs $12M |
Q1 2026 Feb 24, 2026 | -$0.22-9.9% vs -$0.20 | $5M-41.5% vs $9M |
Q3 2025 Aug 28, 2025 | -$0.20-5.7% vs -$0.19 | $915,110-28.9% vs $1M |
Q1 2025 Feb 26, 2025 | -$0.10+29.2% vs -$0.14 | $5M+553.1% vs $696,994 |
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $6.08 and traded as low as $3.13. Prima BioMed shares last traded at $3.17, with a volume of 6,783 shares traded. Analyst Ratings Changes Several
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year.
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 760,586 shares, a decrease of 36.4% from the July 30th total of 1,195,547 shares. Based on an average daily trading volume, of 136,177
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima BioMed shares last traded at $0.4035, with a volume of 199,287 shares. Analyst Ratings Changes IMMP has been the subject
Benchmark IMMP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Immutep Limited (IMMP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.34 | $24.61M | -0.45 | 182.31% | -544.79% | -75.62% | — | |
| $1.73 | $123.77M | -1.00 | — | — | -48.58% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $4.37 | $177.42M | 8.17 | 55.25% | 58.87% | 6.24% | 23.45% |
Immutep Limited (IMMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IMMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Immutep Limited (IMMP) stock FAQ — growth, dividends, profitability & financials explained
Immutep Limited (IMMP) reported $14.2M in revenue in fiscal year 2026.
Immutep Limited (IMMP) grew revenue by 182.3% in fiscal year 2026, compared with the prior fiscal year.
No. Immutep Limited (IMMP) reported a net loss of $77.6M in fiscal year 2026.
Immutep Limited (IMMP) had a return on equity (ROE) of -75.6% in fiscal year 2026. A negative ROE means the company lost money over the period.
Immutep Limited (IMMP) had negative free cash flow of $54.3M in fiscal year 2026.
